{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:20Z","timestamp":1792197260546,"version":"4.4.0"},"reference-count":60,"publisher":"Impact Journals, LLC","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,4]]},"DOI":"10.18632\/oncotarget.18216","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T05:26:40Z","timestamp":1495776400000},"page":"43662-43677","source":"Crossref","is-referenced-by-count":19,"title":["Targeting BCR-ABL+ stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex"],"prefix":"10.18632","volume":"8","author":[{"given":"Min","family":"Chen","sequence":"first","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Turhan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Paris Sud University Hospitals, University Paris Sud 11 and INSERM U935, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Ding","sequence":"additional","affiliation":[{"name":"Shenogen Pharma Group Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingcong","family":"Lin","sequence":"additional","affiliation":[{"name":"Shenogen Pharma Group Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Meng","sequence":"additional","affiliation":[{"name":"Shenogen Pharma Group Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Melo","year":"2001","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/cncr.25690","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives","volume":"117","author":"Wetzler","year":"2011","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/cncr.28598","article-title":"Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"120","author":"Shurtleff","year":"2014","journal-title":"Cancer"},{"key":"5","first-page":"85","volume-title":"Targeting the Chronic Myeloid Leukemia Stem Cell: A paradigm for the curative treatment of human malignancies, myeloid leukemia - basic mechanisms of leukemogenesis","author":"Krug","year":"2001"},{"key":"6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Witte","year":"1990","journal-title":"Science"},{"key":"7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Skorski","year":"2010","journal-title":"J Clin Invest"},{"key":"8","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-06-4312","article-title":"BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia","volume":"67","author":"Bhatia","year":"2007","journal-title":"Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1021\/mp300405n","article-title":"Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation","volume":"10","author":"Lim","year":"2013","journal-title":"Mol Pharm"},{"key":"10","doi-asserted-by":"publisher","first-page":"e7439","DOI":"10.1371\/journal.pone.0007439","article-title":"A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice","volume":"4","author":"Druker","year":"2009","journal-title":"PLoS One"},{"key":"11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Neel","year":"2002","journal-title":"Cancer Cell"},{"key":"12","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/blood-2015-06-653006","article-title":"Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1","volume":"127","author":"Van Etten","year":"2016","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Lydon","year":"1996","journal-title":"Nat Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia","volume":"9","author":"Sawyers","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"16","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Druker","year":"2005","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"Deininger","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Eaves","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","article-title":"Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors","volume":"10","author":"O\u2019Hare","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"21","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Sawyers","year":"2003","journal-title":"Oncogene"},{"key":"22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Sawyers","year":"2004","journal-title":"Science"},{"key":"23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Daley","year":"2005","journal-title":"Cancer Cell"},{"key":"24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Klei","year":"2006","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Haluska","year":"2012","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Abruzzese","year":"2013","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Forman","year":"2003","journal-title":"Blood"},{"key":"29","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Eaves","year":"2007","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker","year":"2011","journal-title":"J Clin Invest"},{"key":"31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/onc.2010.458","article-title":"A positive feedback loop of ER-alpha36\/EGFR promotes malignant growth of ER-negative breast cancer cells","volume":"30","author":"Wang","year":"2011","journal-title":"Oncogene"},{"key":"32","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1073\/pnas.0603339103","article-title":"A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling","volume":"103","author":"Deuel","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 3","key":"33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.mce.2015.04.017","article-title":"Estrogen receptor alpha-36 (ER-alpha36): A new player in human breast cancer","volume":"418","author":"Yin","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"34","doi-asserted-by":"publisher","first-page":"e9013","DOI":"10.1371\/journal.pone.0009013","article-title":"ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK\/ERK and PI3K\/Akt pathways","volume":"5","author":"Sun","year":"2010","journal-title":"PLoS One"},{"key":"35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/omi.2010.0108","article-title":"Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression","volume":"15","author":"Carruba","year":"2011","journal-title":"OMICS"},{"key":"36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.bbrc.2005.08.226","article-title":"Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66","volume":"336","author":"Deuel","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"37","doi-asserted-by":"publisher","first-page":"e71347","DOI":"10.1371\/journal.pone.0071347","article-title":"Icaritin synergistically enhances the radiosensitivity of 4T1 breast cancer cells","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejphar.2004.10.002","article-title":"Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells","volume":"504","author":"Lou","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"39","doi-asserted-by":"publisher","first-page":"e16781","DOI":"10.1371\/journal.pone.0016781","article-title":"Icaritin causes sustained ERK1\/2 activation and induces apoptosis in human endometrial cancer cells","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"key":"40","doi-asserted-by":"publisher","first-page":"10460","DOI":"10.18632\/oncotarget.3399","article-title":"Icaritin suppresses multiple myeloma, by inhibiting IL-6\/JAK2\/STAT3","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"41","doi-asserted-by":"publisher","first-page":"31927","DOI":"10.18632\/oncotarget.5578","article-title":"A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6\/Jak2\/Stat3 pathway","volume":"6","author":"Bi","year":"2015","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"publisher","first-page":"e23720","DOI":"10.1371\/journal.pone.0023720","article-title":"Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK\/ERK\/JNK and JAK2\/STAT3 \/AKT signalings","volume":"6","author":"Xu","year":"2011","journal-title":"PLoS One"},{"key":"43","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.bjc.6602190","article-title":"Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation","volume":"91","author":"Bourhis","year":"2004","journal-title":"Br J Cancer"},{"key":"44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fphar.2016.00191","article-title":"Anti-cancer properties of the naturally occurring aphrodisiacs: icariin and its derivatives","volume":"7","author":"Goh","year":"2016","journal-title":"Front Pharmacol"},{"key":"45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3747\/co.v15i2.224","article-title":"An approach to the management of chronic myeloid leukemia in British Columbia","volume":"15","author":"Smith","year":"2008","journal-title":"Curr Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"47","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","article-title":"Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate","volume":"116","author":"Lehn","year":"2010","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Handgretinger","year":"2005","journal-title":"J Immunol"},{"key":"49","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V92.4.1390","article-title":"The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic\/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology","volume":"92","author":"Gordon","year":"1998","journal-title":"Blood"},{"key":"50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Saw","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"51","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Jiang","year":"2014","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Boque","year":"2010","journal-title":"N Engl J Med"},{"key":"53","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1007\/s13277-015-4006-x","article-title":"Role of ER-alpha36 in breast cancer by typical xenoestrogens","volume":"36","author":"Pan","year":"2015","journal-title":"Tumour Biol"},{"key":"54","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.3892\/or.2012.1722","article-title":"Involvement of ER-alpha36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells","volume":"27","author":"Wang","year":"2012","journal-title":"Oncol Rep"},{"key":"55","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/onc.2009.513","article-title":"c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation","volume":"29","author":"Zhong","year":"2010","journal-title":"Oncogene"},{"key":"56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1593\/neo.91576","article-title":"Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer","volume":"12","author":"Wang","year":"2010","journal-title":"Neoplasia"},{"key":"57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/leu.2010.257","article-title":"Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells","volume":"25","author":"Bhatia","year":"2011","journal-title":"Leukemia"},{"key":"58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Arlinghaus","year":"2011","journal-title":"Leukemia"},{"key":"59","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Marais","year":"2011","journal-title":"Cancer Cell"},{"key":"60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nature15742","article-title":"Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells","volume":"528","author":"Balani","year":"2015","journal-title":"Nature"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T21:58:20Z","timestamp":1659045500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":60,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2017,7,4]]}},"alternative-id":["18216","28599273"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18216","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}